UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 26, 2004
BIOANALYTICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
| Indiana | 0-23357 | 35-1345024 |
(State or other jurisdiction of
incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) |
|
2701 Kent Avenue
West Lafayette, Indiana | |
47906-1382 |
| (Address of principal executive offices) | | (Zip Code) |
|
| (765) 463-4527 |
| | (Registrant's telephone number, including area code) |
The information in this Form 8-K is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
Item 7. Financial Statements and Exhibits.
(a) Not applicable.
(b) Not applicable.
(c) Exhibits
99.1 Bioanalytical Systems, Inc. press release, issued July 26, 2004.
Item 9. Regulation FD Disclosure.
On July 26, 2004, Bioanalytical Systems, Inc. (the "Company") issued a press release announcing that the Company has reached an agreement (in principle) providing for the sale and leaseback of the building that currently houses its clinical research facility in downtown Baltimore, Maryland. BASi will receive $7.75 million in cash from the transaction and will lease 85% of the building for two years at near market rate. Proceeds from the transaction will be used to reduce debt. Closing of the transaction is subject to satisfactory completion of due diligence and execution of a definitive purchase agreement.
The full text of the press release is furnished as exhibit 99.1 to this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 4, 2004 | Bioanalytical Systems, Inc.
By: /s/ Michael R. Cox
Michael R. Cox
VP-Finance, Chief Financial Officer and
Treasurer |
Exhibit Index
Exhibit No.
99.1 | Description
Bioanalytical Systems, Inc. press release, issued July 26, 2004. |
